Managing relapse of CML using therapeutic imatinib plasma level.
Onitilo
Adedayo A
AA
Department of Hematology and Oncology, Marshfield Clinic Weston Center, Weston, WI 54476, USA. onitilo.adedayo@marchfieldclinic.org
Engel
Jessica M
JM
D001549:Benzamides; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000517:prevention & control*; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate